LTR Pharma (ASX:LTP) SPONTAN® pivotal clinical study completes recruitment and dosing
By API User
Melbourne, Australia – LTR Pharma Limited (ASX:LTP), a leading pharmaceutical company, is excited to announce the successful completion of recruitment and dosing phases in its pivotal clinical study of SPONTAN®, a revolutionary nasal spray designed to treat erectile dysfunction (ED). This marks a significant milestone in the development of SPONTAN, setting the stage for a … Continued